Business Wire

CORONA

Share
Corona Cero Brings Same Seats as from Olympic Games Venues to Iconic Sunset Destinations Around the World

Today, Corona Cero, the global beer sponsor of the Olympic & Paralympic Games, unveils its Golden Venues activation, bringing the same seats as from the Olympic Games venues in Paris to iconic travel destinations across four continents. This initiative invites fans to reconnect with nature and gives them the opportunity to embrace their own Golden Moments every day as part of Corona Cero’s ‘For Every Golden Moment’ platform. This activation uses the same seats as from some of the Olympic Games venues in Paris, like Champ de Mars, Grand Palais, and Le Concorde and placed them in iconic travel destinations worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722637366/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Greece - Corona Cero Golden Venues activation (Photo: Corona Cero)

The brand is featuring Golden Venues in 11 breath-taking outdoor settings across 9 countries, including renowned spots such as Arpoador beach in Rio de Janeiro, Brazil, the Grand Peninsula Lagonissi in Athens, Greece, and Café Del Mar in Cartagena, Colombia, offering panoramic views of their respective landscapes. The locations were selected for their remarkable sunsets, scenic beauty and cultural significance, offering visitors a unique opportunity to enjoy a touch of the Olympics amidst spectacular natural settings.

“From Greece, Brazil, Japan, South Africa and Argentina, Corona Cero is offering this gift to fans as an opportunity to experience the Olympic golden moment feeling through Golden Venues,” said Clarissa Pantoja, Vice President of Corona Global. “By bringing the same seats as from Olympic Games stadiums used throughout Paris to these incredible locations worldwide, we are reminding fans that golden moments not only exist within the Olympic Games, but also in the beauty of nature that’s around all of us.”

Corona, recognized as the world’s most valuable beer brand in Kantar’s BrandZ global 2024 rankings, has a rich history of promoting outdoor experiences and encouraging environmental stewardship. The brand is committed to fostering connections and creating meaningful moments in locations that resonate with fans globally.

The full list of Golden Venues spans:

Europe

  • Grand Peninsula Lagonissi in Athens, Greece, a popular beach and sailing destination on the Athenian Riviera with panoramic views of the Saronic Gulf;
  • Thames Riverfront in Battersea, London, UK, a bustling district with local and tourist attractions, including a riverside promenade, ecological areas, and sports facilities;

South America

  • Arpoador Beach in Rio de Janeiro, Brazil, next to Ipanema beach, this landmark destination is renowned for surfing and the best sunset views in town;
  • Café Del Mar in Cartagena, Colombia, located 150m high at the top of Old Town, Cafe Del Mar offers 360-views of Cartagena and is known for its stunning sunsets;
  • Coatepeque Volcano, El Salvador, a volcanic crater located 745 meters above sea level overlooking a 50,000 years old lake;
  • San Carlos de Bariloche, Argentina, a popular ski destination in the Argentinean Patagonia, surrounded by scenic forests and mountains;
  • Pichilemu in Punta de Lobos, Chile, a distinct beach with gray sand and large cliffs, Pichilemu is the heart of surf culture in Chile where many of the country's best surfers learned their skills;

Asia

  • Morito Beach in Kanagawa, Japan, known for its stunning views of Mt. Fuji, Morito Beach is one of the most famous spots on the coast of the Miura Peninsula;

Africa

  • South Africa (three locations) including Cape Town’s Signal Hill, offering panoramic views of V&A Waterfront, the Atlantic Ocean, Lion’s Head, and the iconic Table Mountain, one of the world's Seven Wonders of Nature.

“As the world anticipates the start of the Olympics, we are proud to see Corona Cero bring a touch of the Games to these global iconic locations for more fans to connect to their golden moments,” said Anne-Sophie Voumard, Managing Director IOC Television & Marketing Services. “We hope this gift will inspire people to embrace their own celebratory moments everyday!”

Fans can take in the beauty of nature while celebrating life’s golden moments – together with a refreshing Corona Cero served with a lime, or in any way they prefer to unwind and reconnect with nature. In select locations, the brand is also offering Sunset Hours, which are free concerts by local bands near the Golden Venues locations.

As the first-ever global beer sponsor of the Olympic Games, the no-alcohol beer brand is also elevating the role of moderation in Olympic celebrations globally, creating spaces and moments for cheers and choice in meaningful locations that matter to fans.

AB InBev brands have seen countless new friendships, connections, and experiences built on a shared love of sport and are pleased to be a part of that legacy with decades of historic, award-winning and responsible sports marketing.

The Golden Venues will be open to the public daily during the Olympic Games, starting July 23 with plans to remain in the area after the games.

###

About Corona Global
Corona, an AB InBev global brand*, is the iconic beer brand that is synonymous with paradise with a presence in 180 countries. Recognized as the world’s most valuable beer brand in Kantar’s BrandZ global 2024 rankings, Corona invites the world outside, beckoning you to reconnect with your essential nature and embrace the simple pleasures of life. But it's not just about the beer – it's about the ritual. The ritual of adding a slice of lime to your Corona, an experience that elevates the moment. Corona isn't just a beverage; it's nature in a bottle. And we strive to help protect nature and have become the first global beverage brand with a net-zero plastic footprint. This builds on our longstanding ambition to help protect the world’s oceans and beaches from plastic pollution. Every sip of Corona is a celebration of nature and the beauty of the world around us.

*Corona is not sold by AB InBev in the United States.

About The International Olympic Committee
The International Olympic Committee is a not-for-profit independent international organisation made up of volunteers, which is committed to building a better world through sport. It redistributes more than 90 per cent of its income to the wider sporting movement, which means that every day the equivalent of USD 4.25 million goes to help athletes and sports organisations at all levels around the world.

About AB InBev
AB InBev is a publicly traded company (Euronext: ABI) based in Leuven, Belgium, with secondary listings on the Mexico (MEXBOL: ANB) and South Africa (JSE: ANH) stock exchanges and with American Depositary Receipts on the New York Stock Exchange (NYSE: BUD). As a company, we dream big to create a future with more cheers. We are always looking to serve up new ways to meet life’s moments, move our industry forward and make a meaningful impact in the world. We are committed to building great brands that stand the test of time and to brewing the best beers using the finest ingredients. Our diverse portfolio of well over 500 beer brands includes global brands Budweiser®, Corona®, Stella Artois® and Michelob Ultra®; multi-country brands Beck’s®, Hoegaarden® and Leffe®; and local champions such as Aguila®, Antarctica®, Bud Light®, Brahma®, Cass®, Castle®, Castle Lite®, Cristal®, Harbin®, Jupiler®, Modelo Especial®, Quilmes®, Victoria®, Sedrin®, and Skol®. Our brewing heritage dates back more than 600 years, spanning continents and generations. From our European roots at the Den Hoorn brewery in Leuven, Belgium. To the pioneering spirit of the Anheuser & Co brewery in St. Louis, US. To the creation of the Castle Brewery in South Africa during the Johannesburg gold rush. To Bohemia, the first brewery in Brazil. Geographically diversified with a balanced exposure to developed and developing markets, we leverage the collective strengths of approximately 155,000 colleagues based in nearly 50 countries worldwide. For 2023, AB InBev’s reported revenue was 59.4 billion USD (excluding JVs and associates).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240722637366/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release

Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release

FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release

The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie

Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release

Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c

Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release

Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye